Could a $0.50 heartburn pill ease sickle cell pain?

NCT ID NCT05084521

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small pilot study tested whether famotidine, a widely used heartburn drug, can reduce a blood marker linked to painful crises in children with sickle cell disease. Thirty children took the medicine for 29 days. The goal was to see if the drug lowers P-selectin levels, which might lead to fewer pain episodes. Results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
famotidine
What this could lead to
If it works, this could point toward a simple, safe treatment to reduce painful crises in children with sickle cell disease.
What could go wrong
This is a small pilot study with only 30 children and no placebo group, so results may not be definitive. It only measures a blood marker, not actual crisis reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Necker - Enfants malades Hospital; Department of Pediatrics and Infectious Diseases

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.